News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Acrux Limited Announces Positive Clinical Trial Results with Combination Contraceptive Sprays
July 3, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Acrux (ASX: ACR) -- The Australian drug delivery company, today announced positive results from its Phase 1 clinical studies using two unique contraceptive skin sprays, each containing a progestin and an estrogen.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Australia
MORE ON THIS TOPIC
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
January 22, 2026
·
2 min read
·
Tristan Manalac
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
January 22, 2026
·
1 min read
·
Jennifer Smith-Parker
Insights
The New Gold Rush in Brain Science
January 22, 2026
·
5 min read
·
Jennifer Smith-Parker
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
January 21, 2026
·
1 min read
·
Heather McKenzie
